The Emmes Corporation today announced that it was awarded a contract from the National Institutes of Health to support pediatric clinical trials sponsored by the National Institute of Child Health and Human Development (NICHD). Valued at nearly $70 million, the 10-1/2 year contract will support the NIH’s effort to improve the labeling of drugs for pediatric use.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $23 million to develop a novel multi-drug auto-injector for nerve agent antidote delivery. Emergent’s device is being designed for intramuscular self- or buddy-administration of antidotes for use in military environments and for civilian emergencies.
Adam Havey, executive vice president, business operations at Emergent BioSolutions, said, “Ease of use and rapid delivery of antidotes are critical features of auto-injectors that are intended to mitigate the health effects of nerve agent exposure. Emergent’s device seeks to satisfy the requirements of the Department of Defense for a novel auto-injector platform technology, and we look forward to collaborating with our development partners to meet the DoD’s needs.”
It’s an exciting time to be in Montgomery County. Discover the diverse tapestry of business success in the We Are Montgomery County video series, and consider sharing your unique perspective with us. From our highly-educated talent and regional connectivity to our culturally rich communities and superb quality of life, there’s no better time to be in MoCo.
MedImmune and Sanofi Pasteur are creating and marketing MEDI8897, a drug that aims to prevent lower respiratory tract illnesses that stem from respiratory syncytial virus.
Respiratory syncytial virus, which has symptoms that are related to colds, leads the way when it comes to what gives children and infants lower respiratory tract illness.
Over the past year, Johns Hopkins University has played an integral role in bringing a nationwide program designed to boost small businesses to Baltimore and helping it flourish.
Today, program partners Goldman Sachs and Bloomberg Philanthropies announced a five-year, $10 million commitment to continue the program in Baltimore and named JHU the host site.
WellDoc® and the American Association of Diabetes Educators (AADE) announce the collaborative launch of “The Diabetes Digital Health Learning Network” at the AADE17 conference. The goal of this Learning Network is to assist diabetes educators in gaining next-generation skills in using digital health therapeutics to improve clinical care and outcomes cost-effectively. “As a digital health leader, WellDoc is proud to launch ‘The Diabetes Digital Health Learning Network’ in collaboration with AADE to support its members who are on the front lines of diabetes care and management,” said WellDoc President and CEO Kevin McRaith. “This is a natural progression of our already-established partnership with AADE that began with our collaboration to incorporate The AADE Diabetes Education Curriculum into our FDA-cleared digital therapeutic platform, BlueStar®.”
Gilead Sciences, under intense investor pressure to do a significant M&A deal, may have found a target it likes. It is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.
The Evening Standard, citing unnamed sources, said that Gilead Sciences is considered the most likely candidate to win a bid for United Therapeutics. But the newspaper also said that GSK has Citi and Lazard helping it assess the United, a company founded in 1996 on a pulmonary arterial hypertension (PAH) drug that had been discarded by GSK.
You are invited to travel with County Executive Ike Leggett, MCEDC, other county officials and select area business leaders on an exclusive Business Development trip to South Korea and China, October 20-29, 2017. Our delegation will visit some of the most forward-thinking technology hubs and global commerce destinations of East Asia including Seoul, Daejeon, Xi’an and Shanghai.
Women of the Virginia bioscience community from across the state will lead this full day event offering examples of working together to build a stronger bioscience industry, stronger companies and institutions, stronger teams and networks, and stronger individuals.
Overview: 3iDx is an early stage company developing a new technology platform that is able to isolate and analyze microbes directly from samples for the purpose of identifying antimicrobial resistant strains in less than an hour without having to wait for up to a week for blood culture results. Their ultimate aim is to create a 15-minute test that runs in a battery powered handheld device.
Goal: Our goal is to enable true precision medicine for infection. We see this as the largest single global healthcare issue today, as measured in lives and dollars.
New this year, we’re co-locating our event with The MedTech Conference powered by AdvaMed, to San Jose, CA!
Join us for this important program that dives into the changing landscape and the issues facing our pathway to greater innovation. This year’s theme is “Partnering for Breakthroughs in Pediatric Surgery and Care.”
Albeit small, Baltimore’s startup community is a thriving one. Just 45 minutes outside of the District, the city’s innovation scene is rich with opportunity and talent.
Maybe that’s why Baltimore is one of the most successful places working with Venture for America, a two-year salaried fellowship program that matches recent college grads with startups in 18 different cities.
As Inova Health System prepares to open its new personalized health accelerator this fall, startups recently learned the terms of winning a spot there.
Inova plans to offer $75,000 in funding in exchange for 10 percent equity in early-stage companies selected to join the accelerator, Managing Director Hooks Johnston told an audience at a D.C. event last week. Johnston went on to say, according to Technical.ly DC, companies that make it through an individualized program for four or five months and can get $250,000 in third-party commitments can receive an Inova match.
Join more than 400 of the region’s business, government and community leaders for the Economic Alliance of Greater Baltimore’s Annual Meeting, December 12, 2017 at M&T Bank Stadium. As we celebrate our 20th Anniversary, we will take a look back at the success and growth that the region has experienced over the last two decades, while also featuring Greater Baltimore’s future as a global leader. As we celebrate the results of longstanding partnerships that have led to Baltimore’s economic success, we look forward to celebrating the visionaries and leaders who will shape our tomorrow.
The Precision Medicine Policy and Ethics Conference is a forum for national and industry leaders to address the most pressing challenges in the clinical adoption and integration of genomic medicine. The discussion will take place before an audience of providers, policymakers, scientists and academics. Programming for the conference will examine the ethical and regulatory issues surrounding this topic, including integrating precision medicine into physician education and practice, demographic and socioeconomic barriers to widespread access, and the role and rights of patients concerning genetic data.
Georgetown University’s MS in Biotechnology Program seeks biotech companies and labs to provide internships. If you have a project that’s been on the back burner, this is a great opportunity to get it done with quality and qualified interns at no cost to you.
For more information, check out the flyer below and/or contact: Vasna Nontanovan, MS Associate Dir. and Internship Course Dir. vn5@georgetown.edu or 202-687-6136
The Fort Detrick Alliance, in partnership with the Frederick Innovative Technology Center, Inc., will host a Technology Showcase
September 6, 2017 – 4:30 p.m. – 7:30 p.m.
Join us for an evening of networking, innovative technology demonstrations, and a tour of Frederick County’s only business incubator and accelerator, FITCI. This event promises to be an exciting opportunity. Learn about the newest technologies to come into the marketplace and meet with the companies developing them!
Keiretsu Forum Mid-Atlantic Cordially Invites You to Attend Our August 2017 Meetings
Featuring Entrepreneurs and Companies from Technology-(Internet, Software, Security, SaaS, Mobile Systems, etc.), Life Sciences-Pharma-Medical Devices, Consumer Products, Real Estate, & more!
Keiretsu Forum is the world’s largest private equity angel investment network with more than 1350+ accredited investors in 31 North American chapters and 1000+ investors in 21 international chapters, who have invested more than $850m+ in early stage companies in the last 17 years.
Join peers, thought leaders, venture capitalists, and angel investors at this month’s Keiretsu Forum Meeting and see for yourself why Keiretsu Forum is a major force in Private Equity-Angel Investing today.
Last November, Pharmaceutical Online had the privilege of visiting GSK’s U.S. global R&D hub in Upper Providence, Pa. The 1.4-million sq. ft. facility will soon house the company’s consolidated U.S. R&D activities across the areas of HIV and infectious disease, oncology, immune-inflammation, metabolic pathways and cardiovascular, and dermatology. By 2018, it will be home to more than 3,200 employees, who will collaborate on target identification, safety studies, active pharmaceutical ingredient (API) manufacture, and many other R&D-related activities.
AstraZeneca (LSE: AZN) and its research arm MedImmune, today announced the appointment of two internationally-recognized immuno-oncology leaders.
Dr Jean-Charles Soria joins MedImmune as senior vice president, head of oncology innovative medicines, and Dr Geoffrey Kim has been appointed as head of oncology strategic combinations at AstraZeneca.
NIIMBL is pleased to announce the Quick Start Project (QSP) call. The QSP call solicits proposals for open topic, industry-wide projects focused on the NIIMBL mission of advancing biopharmaceutical manufacturing. Proposal Submission Process Details regarding the proposal submission process and required documents can be found in Section 6 of the RFP document.
After several weeks of talks, Discovery Communications Inc. has reached a deal to acquire the owner of HGTV and Travel Channel.
The Silver Spring-based company announced Monday morning that it would acquire Scripps Networks Interactive Inc. in a cash-and-stock deal valued at $14.6 billion. The transaction is valued at $90 per share — roughly a 4 percent premium on Scripps’ Friday closing price of $86.91 and a 34 percent premium on its share price since Scripps ownership began discussing a sale earlier this month.
With more than 15 years as a nonprofit professional, Amanda joins the Fort Detrick Alliance with extensive experience in communications, marketing, fundraising, event planning, public relations, and management. She replaces Eileen Mitchell, who served as Executive Director since December 2015 In her career, Amanda served as the Assistant Director at the Historical Society of Frederick County; Marketing Manager at the National Shrine of Saint Elizabeth Ann Seton; Marketing director of Black Rock Center for the Arts; and Public Relations Specialist at the University System of Maryland at Hagerstown. Amanda has been instrumental in tourism marketing in the region and served for four years on the Tourism Council of Frederick County’s marketing and group sales committees. As a writer and journalist, Amanda published articles in Frederick Magazine, Find It Frederick magazine, Eastern Home and Travel, the Baltimore Sun, and other regional publications. Amanda may be reached at 301-788-9896 or email director@fortdetrickalliance.org Thank you for your continued support of Fort Detrick and the Alliance. We hope to see you at one of our events. If you are interested in becoming a member of the Alliance, please feel free to contact me at director@fortdetrickalliance.org.
Scientists for the first time have successfully edited genes in human embryos to repair a common and serious disease-causing mutation, producing apparently healthy embryos, according to a study published on Wednesday.
With a focus on improving health, driving economic growth, and expanding the country’s research capacity, the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services is the largest public funder of biomedical research in the world. Because of NIH’s central role in supporting science, technology, and innovation, a better understanding of the agency’s footprint may be helpful to the technology-based economic development practitioner community. This edition of Useful Stats utilizes data from NIH’s Research Portfolio Online Reporting Tool (RePORT) and covers each year from 2007 to 2016. The data does not include projects funded by the American Recovery and Reinvestment Act of 2009.
As far as healthcare goes, Boston has historically focused on biotechnology, life sciences, and pharmaceuticals. Until a few years ago, digital health wasn’t a big talking point in the Boston healthcare scene. After a multilateral initiative launched in 2016, however, Boston wants to be regarded as a national leader in digital healthcare investment and activity.
Between now and 2020, we can expect to see a wave of innovation in pharma. But how will the coming drug launches fare in today’s challenging market? Consider these facts: the number of drugs per indication has risen by 37 percent since 2006, while the top company in an indication still commands at least half of the market. At the same time, restrictions to market access are rising in Europe, the United States, and emerging economies as advances in analytics and multichannel engagement open new opportunities to differentiate products.
Join the newly merged Maryland Tech Council for a casual, fun-filled evening where you can relax, network and celebrate with your community of technology, life science, and business professionals.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
